VICTOZA

Peak

liraglutide

NDASUBCUTANEOUSSOLUTION
Approved
Jan 2010
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Glucagon-like Peptide-1 (GLP-1) Agonists

Pharmacologic Class:

GLP-1 Receptor Agonist

Clinical Trials (5)

NCT07225816Phase 1Recruiting

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Started Nov 2025
75 enrolled
Obesity
NCT05479591N/AWithdrawn

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia

Started Jul 2022
0
Diabetes Mellitus, Type 2
NCT04763564Phase 2Terminated

Efficacy of Liraglutide Therapy in Patients With IPAA

Started Mar 2022
8 enrolled
PouchitisIrritable Pouch Syndrome
NCT05111912Phase 2Completed

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

Started Nov 2021
NCT04903509Phase 1Completed

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

Started Jun 2021
95 enrolled
Healthy

Loss of Exclusivity

LOE Date
Jul 9, 2037
138 months away
Patent Expiry
Jul 9, 2037

Patent Records (4)

Patent #ExpiryTypeUse Code
8114833
Aug 13, 2025Expired
SubstanceProduct
8114833*PED
Feb 13, 2026Expired
9968659
Jan 9, 2037
U-2313
9968659*PED
Jul 9, 2037